BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37515661)

  • 1. Incidence and Clinicopathological Features of Differentiated High-Grade Thyroid Carcinomas: An Institutional Experience.
    Jeong SI; Kim W; Yu HW; Choi JY; Ahn CH; Moon JH; Choi SI; Cha W; Jeong WJ; Park SY; Na HY
    Endocr Pathol; 2023 Sep; 34(3):287-297. PubMed ID: 37515661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas.
    Yegen G; Altay AY; Yılmaz İ; İşcan Y; Sormaz İC; Aksakal N; Önder S; Mete Ö
    Endocr Pathol; 2023 Sep; 34(3):279-286. PubMed ID: 37574466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis.
    Poma AM; Macerola E; Ghossein RA; Tallini G; Basolo F
    Thyroid; 2024 Mar; 34(3):314-323. PubMed ID: 38115626
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.
    Na HY; Yu HW; Kim W; Moon JH; Ahn CH; Choi SI; Kim YK; Choi JY; Park SY
    Clin Endocrinol (Oxf); 2022 Jul; 97(1):106-115. PubMed ID: 35343605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiated high grade thyroid carcinomas: Diagnostic consideration and clinical features.
    Tondi Resta I; Gubbiotti MA; Montone KT; Livolsi VA; Baloch ZW
    Hum Pathol; 2024 Feb; 144():53-60. PubMed ID: 38244615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
    Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
    Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonanaplastic follicular cell-derived thyroid carcinoma: mitosis and necrosis in long-term follow-up.
    Skansing DB; Londero SC; Asschenfeldt P; Larsen SR; Godballe C
    Eur Arch Otorhinolaryngol; 2017 Jun; 274(6):2541-2548. PubMed ID: 28293786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDTC-TC) have different clinical behaviour: a retrospective study of 1456 patients.
    Ghossein R; Katabi N; Dogan S; Shaha AR; Tuttle RM; Fagin JA; Ganly I; Xu B
    Histopathology; 2024 Jun; 84(7):1130-1138. PubMed ID: 38528726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.
    Odate T; Oishi N; Kawai M; Tahara I; Mochizuki K; Akaishi J; Ito K; Katoh R; Kondo T
    Endocr Pathol; 2021 Sep; 32(3):347-356. PubMed ID: 33761111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Grade Differentiated Follicular Cell-Derived Thyroid Carcinoma Versus Poorly Differentiated Thyroid Carcinoma: A Clinicopathologic Analysis of 41 Cases.
    Thompson LDR
    Endocr Pathol; 2023 Jun; 34(2):234-246. PubMed ID: 37195480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.
    Hiltzik D; Carlson DL; Tuttle RM; Chuai S; Ishill N; Shaha A; Shah JP; Singh B; Ghossein RA
    Cancer; 2006 Mar; 106(6):1286-95. PubMed ID: 16470605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poorly differentiated thyroid carcinoma: A hospital-based clinicopathological study and review of literature.
    Win TT; Othman NH; Mohamad I
    Indian J Pathol Microbiol; 2017; 60(2):167-171. PubMed ID: 28631629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
    Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
    Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
    Ibrahimpasic T; Ghossein R; Shah JP; Ganly I
    Thyroid; 2019 Mar; 29(3):311-321. PubMed ID: 30747050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
    Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
    Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases.
    Xu B; David J; Dogan S; Landa I; Katabi N; Saliba M; Khimraj A; Sherman EJ; Tuttle RM; Tallini G; Ganly I; Fagin JA; Ghossein RA
    Histopathology; 2022 Jan; 80(2):322-337. PubMed ID: 34449926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
    Penna GC; Pestana A; Cameselle JM; Momesso D; de Andrade FA; Vidal APA; Araujo Junior ML; Melo M; Fernandes PV; Corbo R; Vaisman M; Sobrinho-Simões M; Soares P; Vaisman F
    Endocrine; 2018 Sep; 61(3):489-498. PubMed ID: 29948935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of differentiated thyroid carcinoma: experience in a developing country.
    Bhargav PR; Mishra A; Agarwal G; Agarwal A; Pradhan PK; Gambhir S; Verma AK; Mishra SK
    World J Surg; 2010 Jan; 34(1):40-7. PubMed ID: 20020292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.